Biodel Inc. (NSDQ:BIOD) announced the results of pre-clinical tests on its candidate for a diabetes treatment called BIOD620.
The tests indicated that the Danbury, Conn.-based company’s insulin product releases the blood-sugar-regulating hormone in response to changing glucose levels.
Biodel said BIOD620, which the company calls a “‘smart’ basal insulin,” is designed to adjust its insulin release profile in response to changing levels of glucose in the bloodstream. BIOD620 is Biodel’s injectable insulin glargine treatment.
The in vitro and in vivo tests used diabetic pigs to compare BIOD620 to Lantus, another insulin glargine product. The glucose levels of the swine injected with BIOD620 went down more quickly than the glucose levels of the pigs treated with Lantus.
Biodel presented its findings at the Annual Meeting and Exposition of the Controlled Release Society in Portland, Ore.
